Similar genetic profile in early and late stage urothelial tract cancer.
Genomic evolution
Molecular subtyping
Phase 1 trials
Targeted therapy
Urothelial tract cancer
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
08 Jul 2024
08 Jul 2024
Historique:
received:
13
05
2024
accepted:
14
06
2024
medline:
8
7
2024
pubmed:
8
7
2024
entrez:
8
7
2024
Statut:
epublish
Résumé
Urothelial tract cancer (UTC) ranks as the tenth most prevalent cancer and holds the seventh position in terms of mortality worldwide. Despite its prevalence and mortality ranking, there are still gaps in the knowledge of the mutational landscape in patients with advanced disease who have limited therapeutic options after multiple lines of prior treatment. This study compares the genomic and transcriptomic landscape, and targeted treatment options between metastatic UTC (mUTC) patients treated with multiple lines of therapy compared to newly diagnosed, untreated Muscle Invasive Bladder Cancer (MIBC). We compared genomic and clinical data from two cohorts: mUTC patients who received multiple lines of therapy and were referred to the Copenhagen Prospective Personalized Oncology (CoPPO) project at Rigshospitalet, University of Copenhagen. Data for MIBC UTC patients were acquired from the Cancer Genome Atlas Bladder Cancer (TCGA BLCA) cohort. Biopsies in CoPPO were performed at the time of enrollment. 523 highly important cancer-related genes (TrueSight Oncology-500 targeted sequencing panel) were used from both cohorts for comparative analysis. Analyses included RNA count data to compare predicted molecular subtypes in each cohort separately. Patients from the CoPPO cohort had a lower median age at first-line treatment than the TCGA BLCA cohort, with no significant gender disparity. The predominant histology was urothelial cell carcinoma in both cohorts. Genomic analysis revealed no significant difference between the top mutated genes in the two cohorts, specifically looking into DNA damage repair genes. Molecular subtyping indicated a higher frequency of neuroendocrine differentiation in the CoPPO cohort. 13% of patients in the CoPPO cohort received targeted therapy based on genomic findings, and 16% received non-targeted treatment, totaling 29% receiving CoPPO treatment (9 patients). The remaining 71% received best supportive care. Kaplan-Meier analysis showed a non-significant survival benefit for the intervention group in the CoPPO cohort. When focusing on 523 highly relevant cancer genes, the mutational profile of mUTC patients who have undergone numerous treatment lines resembles that of newly diagnosed MIBC. These alterations can be targeted, indicating the potential advantage of early genomic testing for personalized treatment within clinical trials.
Identifiants
pubmed: 38976041
doi: 10.1007/s00432-024-05850-y
pii: 10.1007/s00432-024-05850-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
339Informations de copyright
© 2024. The Author(s).
Références
Ahlborn LB, Madsen M, Jonson L et al (2017) Concordance of mutation detection in circulating Tumor DNA in early clinical trials using different blood Collection Protocols. Clin Lab 63:1755–1759. https://doi.org/10.7754/CLIN.LAB.2017.170516
doi: 10.7754/CLIN.LAB.2017.170516
pubmed: 29035458
Ahlborn LB, Tuxen IV, Mouliere F et al (2018) Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors. Oncotarget 9:32570–32579. https://doi.org/10.18632/oncotarget.25948
doi: 10.18632/oncotarget.25948
pubmed: 30220966
pmcid: 6135692
Bellmunt J, Von Der Maase H, Mead GM et al (2012) Randomized phase III study comparing paclitaxel/cisplatin/ gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. J Clin Oncol 30:1107–1113. https://doi.org/10.1200/JCO.2011.38.6979
doi: 10.1200/JCO.2011.38.6979
pubmed: 22370319
pmcid: 3341152
Bernardo C, Eriksson P, Marzouka N, al dain et al (2019) Molecular pathology of the luminal class of urothelial tumors. J Pathol 249:308–318. https://doi.org/10.1002/path.5318
doi: 10.1002/path.5318
pubmed: 31232464
pmcid: 6851980
Birkbak NJ, Wang ZC, Kim JY et al (2012) Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2:366–375. https://doi.org/10.1158/2159-8290.CD-11-0206/42935/P/TELOMERIC-ALLELIC-IMBALANCE-INDICATES-DEFECTIVE .
doi: 10.1158/2159-8290.CD-11-0206/42935
pubmed: 22576213
pmcid: 3806629
Carroll D, McEwen R, Kozarewa I et al (2019) Correlation of circulating tumor DNA (ctDNA), tissue-based genomic profiling and clinical efficacy in the biomarker directed Ph1b trial in metastatic bladder cancer (BISCAY). 4553–4553. https://doi.org/10.1200/JCO.2019.37.15_SUPPL.4553 . https://doi.org/101200/JCO20193715_suppl4553 37
Cathomas R, Lorch A, Bruins HM et al (2022) The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. Eur Urol 81:95–103
doi: 10.1016/j.eururo.2021.09.026
pubmed: 34742583
Chakravarty D, Gao J, Phillips S et al (2017) OncoKB: a Precision Oncology Knowledge Base. JCO Precis Oncol 1:1–16. https://doi.org/10.1200/PO.17.00011
doi: 10.1200/PO.17.00011
Choi W, Porten S, Kim S et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152–165. https://doi.org/10.1016/J.CCR.2014.01.009
doi: 10.1016/J.CCR.2014.01.009
pubmed: 24525232
pmcid: 4011497
R Core Team (2020) R Core Team (2020)
Crabb SJ, Hussain S, Soulis E et al (2023) A Randomized, Double-Blind, Biomarker-Selected, phase II clinical trial of maintenance poly ADP-Ribose polymerase inhibition with Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma. J Clin Oncol 41:54–64. https://doi.org/10.1200/JCO.22.00405
doi: 10.1200/JCO.22.00405
pubmed: 35960902
Damrauer JS, Hoadley KA, Chism DD et al (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 111:3110–3115. https://doi.org/10.1073/PNAS.1318376111
doi: 10.1073/PNAS.1318376111
pubmed: 24520177
pmcid: 3939870
Damrauer JS, Beckabir W, Klomp J et al (2022) Collaborative study from the bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nat Commun 13:6658. https://doi.org/10.1038/s41467-022-33980-9
doi: 10.1038/s41467-022-33980-9
pubmed: 36333289
pmcid: 9636269
Eich ML, Dyrskjøt L, Netto GJ (2017) Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. Virchows Arch 471:271–280. https://doi.org/10.1007/S00428-017-2119-X/FIGURES/7
doi: 10.1007/S00428-017-2119-X/FIGURES/7
pubmed: 28429075
Freedman ND, Silverman DT, Hollenbeck AR et al (2011) Association between smoking and risk of bladder cancer among men and women. JAMA 306:737–745. https://doi.org/10.1001/JAMA.2011.1142
doi: 10.1001/JAMA.2011.1142
pubmed: 21846855
pmcid: 3441175
Fulton B, Jones R, Powles T et al (2020) ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials 21. https://doi.org/10.1186/S13063-020-04283-5
Gamba T, Paparo J, Panepinto O et al (2023) Poly (ADP-Ribose) polymerase inhibitors in patients with Urothelial Cancer. Clin Genitourin Cancer 21:509–516. https://doi.org/10.1016/j.clgc.2023.07.009
doi: 10.1016/j.clgc.2023.07.009
pubmed: 37500375
Goutas D, Palamaris K, Stofas A et al (2023) Immunohistochemical Study of Bladder Cancer Molecular Subtypes and Their Association with PD-L1 expression. Cancers (Basel) 15. https://doi.org/10.3390/cancers15010188
Grivas P, Loriot Y, Morales-Barrera R et al (2021) Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). BMC Cancer. https://doi.org/10.1186/s12885-021-08085-z . 21:
doi: 10.1186/s12885-021-08085-z
pubmed: 34030643
pmcid: 8147008
Hoimes CJ, Flaig TW, Milowsky MI et al (2023) Enfortumab Vedotin Plus Pembrolizumab in previously untreated Advanced Urothelial Cancer. J Clin Oncol 41:22–31. https://doi.org/10.1200/JCO.22.01643/SUPPL_FILE/PROTOCOL_JCO.22.01643.PDF
doi: 10.1200/JCO.22.01643/SUPPL_FILE/PROTOCOL_JCO.22.01643.PDF
pubmed: 36041086
Hu HM, Zhao X, Kaushik S et al (2018) A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP inhibitor resistance. Cell Rep 23:918–929. https://doi.org/10.1016/j.celrep.2018.03.093
doi: 10.1016/j.celrep.2018.03.093
pubmed: 29669295
pmcid: 5935461
Humphrey PA, Moch H, Cubilla AL et al (2016) The 2016 WHO classification of Tumours of the urinary system and male genital organs-Part B: prostate and bladder tumours. Eur Urol 70:106–119. https://doi.org/10.1016/J.EURURO.2016.02.028
doi: 10.1016/J.EURURO.2016.02.028
pubmed: 26996659
Kamoun A, de Reyniès A, Allory Y et al (2020) A Consensus Molecular classification of muscle-invasive bladder Cancer. Eur Urol 77:420–433. https://doi.org/10.1016/j.eururo.2019.09.006
doi: 10.1016/j.eururo.2019.09.006
pubmed: 31563503
Lavallee E, Sfakianos JP, Mulholland DJ (2021) Tumor heterogeneity and consequences for bladder cancer treatment. Cancers (Basel) 13. https://doi.org/10.3390/CANCERS13215297
Li Q, Damish AW, Frazier Z et al (2019) ERCC2 helicase domain mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in muscle-invasive bladder Cancer. Clin Cancer Res 25:977–988. https://doi.org/10.1158/1078-0432.CCR-18-1001
doi: 10.1158/1078-0432.CCR-18-1001
pubmed: 29980530
Liu D, Plimack ER, Hoffman-Censits J et al (2016) Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol 2:1094–1096
doi: 10.1001/jamaoncol.2016.1056
pubmed: 27310333
pmcid: 5515075
Loehrer PJ, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066–1073. https://doi.org/10.1200/JCO.1992.10.7.1066
doi: 10.1200/JCO.1992.10.7.1066
pubmed: 1607913
Loriot Y, Necchi A, Park SH et al (2019) Erdafitinib in locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 381:338–348. https://doi.org/10.1056/nejmoa1817323
doi: 10.1056/nejmoa1817323
pubmed: 31340094
Marzouka NAD, Eriksson P, Rovira C et al (2018) A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep 8. https://doi.org/10.1038/S41598-018-22126-X
Mayakonda A, Lin DC, Assenov Y et al (2018) Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res 28:1747–1756. https://doi.org/10.1101/GR.239244.118
doi: 10.1101/GR.239244.118
pubmed: 30341162
pmcid: 6211645
McLaren W, Gil L, Hunt SE et al (2016) The Ensembl variant effect predictor. Genome Biol 17:1–14. https://doi.org/10.1186/S13059-016-0974-4/TABLES/8
doi: 10.1186/S13059-016-0974-4/TABLES/8
Meeks JJ, Al-Ahmadie H, Faltas BM et al (2020) Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat Rev Urol 17:259–270. https://doi.org/10.1038/S41585-020-0304-1
doi: 10.1038/S41585-020-0304-1
pubmed: 32235944
pmcid: 7968350
Merkhofer CM, Eaton KD, Martins RG et al (2021) Impact of clinical trial participation on survival of patients with metastatic non-small cell Lung Cancer. Clin Lung Cancer 22:523. https://doi.org/10.1016/J.CLLC.2021.04.003
doi: 10.1016/J.CLLC.2021.04.003
pubmed: 34059474
pmcid: 8531178
Mitra AP (2016) Molecular substratification of bladder cancer: moving towards individualized patient management. Ther Adv Urol 8:215–233. https://doi.org/10.1177/1756287216638981
doi: 10.1177/1756287216638981
pubmed: 27247631
pmcid: 4872193
Morera DS, Hasanali SL, Belew D et al (2020) Clinical parameters Outperform Molecular subtypes for Predicting Outcome in bladder Cancer: results from multiple cohorts, including TCGA. J Urol 203:62–72. https://doi.org/10.1097/JU.0000000000000351
doi: 10.1097/JU.0000000000000351
pubmed: 31112107
O’Donnell PH, Milowsky MI, Petrylak DP et al (2023) Enfortumab Vedotin with or without Pembrolizumab in Cisplatin-Ineligible patients with previously untreated locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol 41:4107–4117. https://doi.org/10.1200/JCO.22.02887
doi: 10.1200/JCO.22.02887
pubmed: 37369081
pmcid: 10852367
Patschan O, Sjödahl G, Chebil G et al (2015) A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. Eur Urol 68:824–832. https://doi.org/10.1016/j.eururo.2015.02.021
doi: 10.1016/j.eururo.2015.02.021
pubmed: 25770486
Peeker R (2018) Re: molecular classification of Urothelial Carcinoma: global mRNA classification Versus Tumour-cell phenotype classification. Eur Urol 73:809–810. https://doi.org/10.1016/j.eururo.2017.12.011
doi: 10.1016/j.eururo.2017.12.011
pubmed: 29273405
Peng Y, Li Z, Zhang S et al (2014) Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients. Int J Cancer 135:2687–2696. https://doi.org/10.1002/IJC.28892
doi: 10.1002/IJC.28892
pubmed: 24729390
Powles T, Park SH, Voog E et al (2020) Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 383:1218–1230. https://doi.org/10.1056/nejmoa2002788
doi: 10.1056/nejmoa2002788
pubmed: 32945632
Powles T, Carroll D, Chowdhury S et al (2021a) An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nat Med 27:793–801. https://doi.org/10.1038/s41591-021-01317-6
doi: 10.1038/s41591-021-01317-6
pubmed: 33941921
Powles T, Carroll D, Chowdhury S et al (2021b) An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nat Med 27:793–801. https://doi.org/10.1038/S41591-021-01317-6
doi: 10.1038/S41591-021-01317-6
pubmed: 33941921
Powles T, Park SH, Caserta C et al (2023) Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: results from the JAVELIN bladder 100 Trial after ≥ 2 years of Follow-Up. J Clin Oncol 41:3486–3492. https://doi.org/10.1200/JCO.22.01792
doi: 10.1200/JCO.22.01792
pubmed: 37071838
pmcid: 10306435
Powles T, Valderrama BP, Gupta S et al (2024) Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med 390:875–888. https://doi.org/10.1056/NEJMOA2312117
doi: 10.1056/NEJMOA2312117
pubmed: 38446675
Rebouissou S, Bernard-Pierrot I, De Reyniès A et al (2014) EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med 6. https://doi.org/10.1126/SCITRANSLMED.3008970
Robertson AG, Kim J, Al-Ahmadie H et al (2017) Comprehensive molecular characterization of muscle-invasive bladder Cancer. Cell 171:540–556e25. https://doi.org/10.1016/J.CELL.2017.09.007
doi: 10.1016/J.CELL.2017.09.007
pubmed: 28988769
pmcid: 5687509
Safiri S, Kolahi AA, Naghavi M et al (2021) Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease study 2019. BMJ Glob Health 6. https://doi.org/10.1136/BMJGH-2020-004128
Saginala K, Barsouk A, Aluru JS et al (2020) Epidemiology of {Bladder} {Cancer}. Med Sci (Basel) 8. https://doi.org/10.3390/medsci8010015
Schulz GB, Todorova R, Rodler S et al (2020) Heterogeneity of PD-L1 expression between primary and metastatic bladder cancer tumors and therapeutic implications between the immune cell score and combined positivity score. J Clin Oncol 38:e17041–e17041. https://doi.org/10.1200/jco.2020.38.15_suppl.e17041
doi: 10.1200/jco.2020.38.15_suppl.e17041
Sjödahl G (2018) Molecular subtype profiling of urothelial carcinoma using a subtype-specific immunohistochemistry panel. Methods in Molecular Biology. Humana Press Inc., pp 53–64
Sjödahl G, Eriksson P, Liedberg F, Höglund M (2017) Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J Pathol 242:113–125. https://doi.org/10.1002/path.4886
doi: 10.1002/path.4886
pubmed: 28195647
pmcid: 5413843
Sjödahl G, Jackson CL, Bartlett JMS et al (2019) Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts. J Pathol 247:563–573
doi: 10.1002/path.5230
pubmed: 30604486
Sjödahl G, Abrahamsson J, Bernardo C et al (2022) Molecular subtypes as a basis for stratified use of Neoadjuvant Chemotherapy for muscle-invasive bladder Cancer—A narrative review. Cancers (Basel) 14:1692
doi: 10.3390/cancers14071692
pubmed: 35406463
Suehnholz SP, Nissan MH, Zhang H et al (2023) Quantifying the Expanding Landscape of clinical actionability for patients with Cancer. Cancer Discov 14:49–65. https://doi.org/10.1158/2159-8290.CD-23-0467/3372948/CD-23-0467.PDF
doi: 10.1158/2159-8290.CD-23-0467/3372948/CD-23-0467.PDF
pmcid: 10784742
Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/CAAC.21660
doi: 10.3322/CAAC.21660
pubmed: 33538338
Tuxen IV, Rohrberg KS, Oestrup O et al (2019) Copenhagen prospective personalized oncology (COPPO)—Clinical utility of using molecular profiling to select patients to phase I trials. Clin Cancer Res 25:1239–1247. https://doi.org/10.1158/1078-0432.CCR-18-1780
doi: 10.1158/1078-0432.CCR-18-1780
pubmed: 30274980
Van Allen EM, Mouw KW, Kim P et al (2014) Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4:1140–1153. https://doi.org/10.1158/2159-8290.CD-14-0623
doi: 10.1158/2159-8290.CD-14-0623
pubmed: 25096233
pmcid: 4238969
Vandekerkhove G, Lavoie J-M, Annala M et al (2019) Genomic concordance between profiling of circulating tumor DNA (ctDNA) and matched tissue in metastatic urothelial carcinoma. 457–457. https://doi.org/10.1200/JCO.2019.37.7_SUPPL.457 . https://doi.org/101200/JCO2019377_suppl457 37
Venkatesan S, Swanton C, Taylor BS, Costello JF (2017) Treatment-Induced mutagenesis and selective pressures sculpt Cancer Evolution. Cold Spring Harb Perspect Med 7. https://doi.org/10.1101/CSHPERSPECT.A026617
Vignani F, Tambaro R, De Giorgi U et al (2023) Addition of Niraparib to best supportive care as maintenance treatment in patients with Advanced Urothelial Carcinoma whose disease did not Progress after First-line platinum-based Chemotherapy: the Meet-URO12 Randomized Phase 2 Trial. Eur Urol 83:82–89. https://doi.org/10.1016/j.eururo.2022.09.025
doi: 10.1016/j.eururo.2022.09.025
pubmed: 36216658
Von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077. https://doi.org/10.1200/JCO.2000.18.17.3068
doi: 10.1200/JCO.2000.18.17.3068
pubmed: 11001674
Wang C, Nie H, Li Y et al (2016) The study of the relation of DNA repair pathway genes SNPs and the sensitivity to radiotherapy and chemotherapy of NSCLC. Sci Rep 2016 6(1 6):1–12. https://doi.org/10.1038/srep26526
doi: 10.1038/srep26526
Waskiewicz E, Vasiliou M, Corcoles-Saez I, Cha RS (2021) Cancer genome datamining and functional genetic analysis implicate mechanisms of ATM/ATR dysfunction underpinning carcinogenesis. Commun Biol 4(1):363. https://doi.org/10.1038/s42003-021-01884-x
Westergren DO, Gårdmark T, Lindhagen L et al (2019) A Nationwide, Population based analysis of patients with Organ confined, muscle invasive bladder Cancer not receiving curative intent therapy in Sweden from 1997 to 2014. J Urol 202:905–912. https://doi.org/10.1097/JU.0000000000000350
doi: 10.1097/JU.0000000000000350
pubmed: 31144594
Witjes JA, Bruins HM, Cathomas R et al (2021) European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 79:82–104 (2013) World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 310:2191–2194